Detalles de la búsqueda
1.
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study.
Hepatol Res
; 51(12): 1229-1241, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34591334
2.
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib.
HPB (Oxford)
; 23(6): 915-920, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33191108
3.
Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches.
Future Oncol
; 11(19): 2697-2710, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26376740
4.
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment.
World J Hepatol
; 14(7): 1319-1332, 2022 Jul 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36158925
5.
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
Crit Rev Oncol Hematol
; 157: 103167, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33271389
6.
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus.
Tumori
; 107(6): 550-555, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33243068
7.
Immune Checkpoint Inhibitors in the Treatment of HCC.
Front Oncol
; 10: 601240, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33585218
8.
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
PLoS One
; 15(5): e0232449, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32379785
9.
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer.
Cancers (Basel)
; 12(5)2020 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32413973
10.
Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients.
J Cell Mol Med
; 13(9B): 3951-9, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18624749
11.
An attempt to correlate a "Multidimensional Geriatric Assessment" (MGA), treatment assignment and clinical outcome in elderly cancer patients: results of a phase II open study.
Crit Rev Oncol Hematol
; 66(1): 75-83, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18164209
12.
Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach.
Front Physiol
; 9: 1294, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30294279
13.
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress.
Cancer Epidemiol Biomarkers Prev
; 15(5): 1030-4, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16702388
14.
Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy.
Nutrition
; 22(2): 136-45, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16459226
15.
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?
Target Oncol
; 11(5): 593-603, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27184491
16.
Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment.
Cancer Epidemiol Biomarkers Prev
; 13(10): 1651-9, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15466983
17.
Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity.
Int J Oncol
; 20(2): 419-27, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11788911
18.
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.
J Exp Ther Oncol
; 3(4): 205-19, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-14567291
19.
Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
Oncol Rep
; 9(4): 887-96, 2002.
Artículo
en Inglés
| MEDLINE | ID: mdl-12066227
20.
Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
Oncol Rep
; 10(1): 197-206, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-12469169